Cargando…

Ozanimod Therapy in a Patient With Ulcerative Colitis and Multiple Sclerosis: Hitting 2 Birds With 1 Stone

Simultaneous occurrence of multiple sclerosis (MS) and ulcerative colitis (UC) is seldom encountered by clinicians and poses unique challenges. The sphingosine-1-phosphate receptor modulator ozanimod has been recently approved for UC. Ozanimod can be used in such scenarios where it can treat both co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vuyyuru, Sudheer K., Morrow, Sarah A., Jairath, Vipul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer 2023
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857283/ https://www.ncbi.nlm.nih.gov/pubmed/36699181 http://dx.doi.org/10.14309/crj.0000000000000955

Ejemplares similares

Ozanimod: A Review in Ulcerative Colitis
por: Paik, Julia
Publicado: (2022)

Ozanimod for multiple sclerosis
Publicado: (2021)

Correction to: Ozanimod: A Review in Ulcerative Colitis
por: Paik, Julia
Publicado: (2022)

Ozanimod-Associated Iatrogenic Kaposi Sarcoma in a Patient With Ulcerative Colitis
por: Sandlow, Sarah, et al.
Publicado: (2023)

Ozanimod Maintenance Therapy After Cyclosporine Induction in Acute Severe Ulcerative Colitis
por: Cohen, Nathaniel A., et al.
Publicado: (2022)

"Hit smart and early" mit Ozanimod
por: Ottenjann, Henrike
Publicado: (2023)

"Hit smart and early" - MS-Therapie mit Ozanimod
por: Ottenjann, Henrike
Publicado: (2023)

Su1480: TREATMENT-EMERGENT COVID-19 INFECTIONS IN OZANIMOD ULCERATIVE COLITIS AND MULTIPLE SCLEROSIS CLINICAL TRIALS
por: Ungaro, Ryan C., et al.
Publicado: (2022)

An Overview of the Efficacy and Safety of Ozanimod for the Treatment of Relapsing Multiple Sclerosis
por: Fronza, Marzia, et al.
Publicado: (2021)

Network pharmacology and in silico pharmacokinetic prediction of Ozanimod in the management of ulcerative colitis: A computational study
por: Sivasakthi, Priya, et al.
Publicado: (2022)

Su1500: COMPARATIVE EFFICACY AND SAFETY OF OZANIMOD AND USTEKINUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
por: Dubinsky, Marla C., et al.
Publicado: (2022)

Immune‐mediated inflammatory diseases of the gastrointestinal tract: Beyond Crohn's disease and ulcerative colitis
por: Vuyyuru, Sudheer K, et al.
Publicado: (2022)

Reliability of the Endoscopic Ultrasound Ulcerative Colitis (EUS-UC) score for assessment of inflammation in patients with ulcerative colitis
por: Yan, Brian M., et al.
Publicado: (2021)

SARS‐CoV‐2 vaccination and infection in ozanimod‐treated participants with relapsing multiple sclerosis
por: Cree, Bruce A. C., et al.
Publicado: (2023)

GRP78 targeting: Hitting two birds with a stone
por: Elfiky, Abdo A., et al.
Publicado: (2020)

Evaluating cost per remission and cost of serious adverse events of advanced therapies for ulcerative colitis
por: Jairath, Vipul, et al.
Publicado: (2022)

Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study
por: Cohen, Jeffrey A, et al.
Publicado: (2018)

Ozanimod to Treat Relapsing Forms of Multiple Sclerosis: A Comprehensive Review of Disease, Drug Efficacy and Side Effects
por: Lassiter, Grace, et al.
Publicado: (2020)

Cost Per Relapse Avoided for Ozanimod Versus Other Selected Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis in the United States
por: Kantor, Daniel, et al.
Publicado: (2023)

Ozanimod for Treatment of Relapsing-Remitting Multiple Sclerosis in Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Sun, Yue, et al.
Publicado: (2020)

Comparative Efficacy and Safety of Ozanimod and Dimethyl Fumarate for Relapsing-Remitting Multiple Sclerosis Using Matching-Adjusted Indirect Comparison
por: Cohan, Stanley, et al.
Publicado: (2021)

Hitting More Birds with a Stone: Impact of TGF-β on ILC Activity in Cancer
por: Fionda, Cinzia, et al.
Publicado: (2020)

Perioperative parathyroid hormone measurements in thyroid surgery: one stone to hit three birds()
por: Terkawi, Abdullah S., et al.
Publicado: (2014)

Definition of mild to moderate ulcerative colitis in clinical trials: A systematic literature review
por: Caron, Bénédicte, et al.
Publicado: (2022)

Neuroprotection by Ozanimod Following Intracerebral Hemorrhage in Mice
por: Wang, Fei, et al.
Publicado: (2022)

Long-Term Efficacy and Safety of Ozanimod in Moderately to Severely Active Ulcerative Colitis: Results From the Open-Label Extension of the Randomized, Phase 2 TOUCHSTONE Study
por: Sandborn, William J, et al.
Publicado: (2021)

Development of the symptoms and impacts questionnaire for Crohn's disease and ulcerative colitis
por: Dulai, Parambir S., et al.
Publicado: (2020)

Correlation of fecal calprotectin and patient-reported outcome measures in patients with ulcerative colitis
por: Kamat, Nagesh, et al.
Publicado: (2022)

Comparative efficacy of advanced treatments in biologic-naïve or biologic-experienced patients with ulcerative colitis: a systematic review and network meta-analysis
por: Lu, Xiaoyan, et al.
Publicado: (2022)

“Two-birds-one-stone” colon-targeted nanomedicine treats ulcerative colitis via remodeling immune microenvironment and anti-fibrosis
por: Zhang, Jiaxin, et al.
Publicado: (2022)

Correction to: Comparative efficacy of advanced treatments in biologic-naïve or biologic-experienced patients with ulcerative colitis: a systematic review and network meta-analysis
por: Lu, Xiaoyan, et al.
Publicado: (2023)

Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial
por: Cree, Bruce AC, et al.
Publicado: (2022)

Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials
por: Harris, Sarah, et al.
Publicado: (2021)

Resolving Histological Inflammation in Ulcerative Colitis With Mirikizumab in the LUCENT Induction and Maintenance Trial Programmes
por: Magro, Fernando, et al.
Publicado: (2023)

Multiple sclerosis and ulcerative colitis: A systematic review and meta-analysis
por: Nabizadeh, Fardin, et al.
Publicado: (2023)

A Literature Review of Ozanimod Therapy in Inflammatory Bowel Disease: From Concept to Practical Application
por: Becher, Noah, et al.
Publicado: (2022)

Effect of the sphingosine-1-phosphate receptor modulator ozanimod on leukocyte subtypes in relapsing MS
por: Harris, Sarah, et al.
Publicado: (2020)

International Consensus on Definition of Mild-to-Moderate Ulcerative Colitis Disease Activity in Adult Patients
por: Caron, Bénédicte, et al.
Publicado: (2023)

iSTART-II: An Update on the i Support Therapy–Access to Rapid Treatment (iSTART) Approach for Patient-Centered Therapy in Mild-to-Moderate Ulcerative Colitis
por: D’Amico, Ferdinando, et al.
Publicado: (2023)

Behcet's Disease With Budd-Chiari Syndrome and Challenges in Its Management
por: Vuyyuru, Sudheer K., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qb5tir8cmilucuteeljo7aoa5f